Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2011 3
2012 4
2013 5
2014 3
2015 2
2016 5
2017 6
2018 4
2019 1
2020 4
2021 4
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Pathway inhibition: emerging molecular targets for treating glioblastoma.
Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Wick W, et al. Neuro Oncol. 2011 Jun;13(6):566-79. doi: 10.1093/neuonc/nor039. Neuro Oncol. 2011. PMID: 21636705 Free PMC article. Review.
Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblastoma treatment. ...This review discusses limitations in the existing therapy for glioblastoma and provides an overview of c …
Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblast
Emerging therapeutic targets for cerebral edema.
Jha RM, Raikwar SP, Mihaljevic S, Casabella AM, Catapano JS, Rani A, Desai S, Gerzanich V, Simard JM. Jha RM, et al. Expert Opin Ther Targets. 2021 Nov;25(11):917-938. doi: 10.1080/14728222.2021.2010045. Epub 2022 Jan 2. Expert Opin Ther Targets. 2021. PMID: 34844502 Free PMC article. Review.
Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging based on a growing understanding of the molecular underpinnings of cerebral edema. AREAS COVERED: We review the pathophysiology and rel …
Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging ba …
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.
Kudinov AE, Karanicolas J, Golemis EA, Boumber Y. Kudinov AE, et al. Clin Cancer Res. 2017 May 1;23(9):2143-2153. doi: 10.1158/1078-0432.CCR-16-2728. Epub 2017 Jan 31. Clin Cancer Res. 2017. PMID: 28143872 Free PMC article. Review.
More recently, the Musashi proteins were found to be overexpressed and prognostic of outcome in numerous cancer types, including colorectal, lung, and pancreatic cancers; glioblastoma; and several leukemias. MSI1 and MSI2 bind and regulate the mRNA stability and translatio …
More recently, the Musashi proteins were found to be overexpressed and prognostic of outcome in numerous cancer types, including colorectal, …
Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
Videla-Richardson GA, Morris-Hanon O, Torres NI, Esquivel MI, Vera MB, Ripari LB, Croci DO, Sevlever GE, Rabinovich GA. Videla-Richardson GA, et al. Int J Mol Sci. 2021 Dec 28;23(1):316. doi: 10.3390/ijms23010316. Int J Mol Sci. 2021. PMID: 35008740 Free PMC article. Review.
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. ...Particularly in GBM, galectins control tumor cell tran …
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the a …
TGF-β2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells' invasion.
Zhang C, Zhang X, Xu R, Huang B, Chen AJ, Li C, Wang J, Li XG. Zhang C, et al. J Exp Clin Cancer Res. 2017 Nov 16;36(1):162. doi: 10.1186/s13046-017-0628-8. J Exp Clin Cancer Res. 2017. PMID: 29145888 Free PMC article. Retracted.
BACKGROUND: Glioblastoma multiforme (GBM) is characterized by lethal aggressiveness and patients with GBM are in urgent need for new therapeutic avenues to improve quality of life. ...Western blot, qPCR, immunofluorescence and transmission-electron microscope were used to …
BACKGROUND: Glioblastoma multiforme (GBM) is characterized by lethal aggressiveness and patients with GBM are in urgent need for new …
Epidermal growth factor receptor: a re-emerging target in glioblastoma.
Hegi ME, Rajakannu P, Weller M. Hegi ME, et al. Curr Opin Neurol. 2012 Dec;25(6):774-9. doi: 10.1097/WCO.0b013e328359b0bc. Curr Opin Neurol. 2012. PMID: 23007009 Review.
Here, we review recent insights into molecular mechanisms relevant for effective targeting of the EGFR pathway. ...SUMMARY: A combination of preclinical and clinical studies at the molecular level has provided new insights that will allow refining stra …
Here, we review recent insights into molecular mechanisms relevant for effective targeting of the EGFR pathway. ...SUMM …
A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas.
Jandrey EHF, Bezerra M, Inoue LT, Furnari FB, Camargo AA, Costa ÉT. Jandrey EHF, et al. Front Oncol. 2021 Jun 10;11:652133. doi: 10.3389/fonc.2021.652133. eCollection 2021. Front Oncol. 2021. PMID: 34178638 Free PMC article. Review.
Drug resistance is mostly driven by tumor cell plasticity: a concept associated with reactivating transcriptional programs in response to adverse and dynamic conditions from the tumor microenvironment. Autophagy, or "self-eating", pathway is an emerging target
Drug resistance is mostly driven by tumor cell plasticity: a concept associated with reactivating transcriptional programs in response to ad …
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges.
Noorani I, Mischel PS, Swanton C. Noorani I, et al. Nat Rev Clin Oncol. 2022 Nov;19(11):733-743. doi: 10.1038/s41571-022-00679-1. Epub 2022 Sep 21. Nat Rev Clin Oncol. 2022. PMID: 36131011 Review.
Glioblastoma evolution is facilitated by intratumour heterogeneity, which poses a major hurdle to effective treatment. ...Notably, targeted therapies inhibiting oncogenic pathways have failed to improve glioblastoma outcomes. ...
Glioblastoma evolution is facilitated by intratumour heterogeneity, which poses a major hurdle to effective treatment. ...Notably,
An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K, Minamoto T. Miyashita K, et al. Anticancer Agents Med Chem. 2009 Dec;9(10):1114-22. doi: 10.2174/187152009789734982. Anticancer Agents Med Chem. 2009. PMID: 19925395 Review.
Improvement in the outcome of cancer patients who are refractory to currently available treatments relies on the development of target-directed therapies. One group of molecular targets with potential clinical relevance is a set of protein tyrosine kinases en …
Improvement in the outcome of cancer patients who are refractory to currently available treatments relies on the development of target
Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
Saunders JT, Holmes B, Benavides-Serrato A, Kumar S, Nishimura RN, Gera J. Saunders JT, et al. J Neurooncol. 2021 Apr;152(2):217-231. doi: 10.1007/s11060-021-03699-6. Epub 2021 Jan 28. J Neurooncol. 2021. PMID: 33511508 Free PMC article.
INTRODUCTION: Recent studies have suggested that dysregulated Hippo pathway signaling may contribute to glioblastoma proliferation and invasive characteristics. The downstream effector of the pathway, the Yes-associated protein (YAP) oncoprotein, has emerg
INTRODUCTION: Recent studies have suggested that dysregulated Hippo pathway signaling may contribute to glioblastoma prolifera …
43 results